International severe asthma registry (ISAR): protocol for a global registry.
Disease registry
Protocol
Real-world
Severe asthma
Journal
BMC medical research methodology
ISSN: 1471-2288
Titre abrégé: BMC Med Res Methodol
Pays: England
ID NLM: 100968545
Informations de publication
Date de publication:
14 08 2020
14 08 2020
Historique:
received:
11
12
2019
accepted:
26
06
2020
entrez:
22
8
2020
pubmed:
21
8
2020
medline:
25
6
2021
Statut:
epublish
Résumé
Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical features and outcomes of severe asthma in order to facilitate personalised and targeted care. The International Severe Asthma Registry (ISAR) is a multi-country registry project initiated to aid in this endeavour. ISAR is a multi-disciplinary initiative benefitting from the combined experience of the ISAR Steering Committee (ISC; comprising 47 clinicians and researchers across 29 countries, who have a special interest and/or experience in severe asthma management or establishment and maintenance of severe asthma registries) in collaboration with scientists and experts in database management and communication. Patients (≥18 years old) receiving treatment according to the 2018 definitions of the Global Initiative for Asthma (GINA) Step 5 or uncontrolled on GINA Step 4 treatment will be included. Data will be collected on a core set of 95 variables identified using the Delphi method. Participating registries will agree to provide access to and share standardised anonymous patient-level data with ISAR. ISAR is a registered data source on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ISAR's collaborators include Optimum Patient Care, the Respiratory Effectiveness Group (REG) and AstraZeneca. ISAR is overseen by the ISC, REG, the Anonymised Data Ethics & Protocol Transparency Committee and the ISAR operational committee, ensuring the conduct of ethical, clinically relevant research that brings value to all key stakeholders. ISAR aims to offer a rich source of real-life data for scientific research to understand and improve disease burden, treatment patterns and patient outcomes in severe asthma. Furthermore, the registry will provide an international platform for research collaboration in respiratory medicine, with the overarching aim of improving primary and secondary care of adults with severe asthma globally.
Sections du résumé
BACKGROUND
Severe asthma exerts a disproportionately heavy burden on patients and health care. Due to the heterogeneity of the severe asthma population, many patients need to be evaluated to understand the clinical features and outcomes of severe asthma in order to facilitate personalised and targeted care. The International Severe Asthma Registry (ISAR) is a multi-country registry project initiated to aid in this endeavour.
METHODS
ISAR is a multi-disciplinary initiative benefitting from the combined experience of the ISAR Steering Committee (ISC; comprising 47 clinicians and researchers across 29 countries, who have a special interest and/or experience in severe asthma management or establishment and maintenance of severe asthma registries) in collaboration with scientists and experts in database management and communication. Patients (≥18 years old) receiving treatment according to the 2018 definitions of the Global Initiative for Asthma (GINA) Step 5 or uncontrolled on GINA Step 4 treatment will be included. Data will be collected on a core set of 95 variables identified using the Delphi method. Participating registries will agree to provide access to and share standardised anonymous patient-level data with ISAR. ISAR is a registered data source on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ISAR's collaborators include Optimum Patient Care, the Respiratory Effectiveness Group (REG) and AstraZeneca. ISAR is overseen by the ISC, REG, the Anonymised Data Ethics & Protocol Transparency Committee and the ISAR operational committee, ensuring the conduct of ethical, clinically relevant research that brings value to all key stakeholders.
CONCLUSIONS
ISAR aims to offer a rich source of real-life data for scientific research to understand and improve disease burden, treatment patterns and patient outcomes in severe asthma. Furthermore, the registry will provide an international platform for research collaboration in respiratory medicine, with the overarching aim of improving primary and secondary care of adults with severe asthma globally.
Identifiants
pubmed: 32819285
doi: 10.1186/s12874-020-01065-0
pii: 10.1186/s12874-020-01065-0
pmc: PMC7439682
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
212Références
J Manag Care Spec Pharm. 2016 Jul;22(7):848-61
pubmed: 27348285
Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23
pubmed: 19892860
J Allergy Clin Immunol Pract. 2019 Feb;7(2):578-588.e2
pubmed: 30179741
Respir Med. 2014 Dec;108(12):1723-32
pubmed: 25456708
J Asthma. 2012 May;49(4):416-22
pubmed: 22443408
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Respir Med. 2018 Dec;145:41-47
pubmed: 30509715
J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1462-1468
pubmed: 30368004
J Allergy Clin Immunol. 2010 Nov;126(5):926-38
pubmed: 20926125
Ann N Y Acad Sci. 2008;1136:161-71
pubmed: 17954679
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):120-9.e3
pubmed: 26439182
Allergy. 2013 Jul;68(7):836-43
pubmed: 23735183
Can Respir J. 2010 Mar-Apr;17(2):74-80
pubmed: 20422063
J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5
pubmed: 23040887
Health Qual Life Outcomes. 2010 Sep 08;8:96
pubmed: 20825674
Hum Mutat. 2013 Nov;34(11):1449-57
pubmed: 23913485
Pneumologie. 2012 Jun;66(6):341-4
pubmed: 22477565
Acta Neurol Scand Suppl. 2012;(195):24-30
pubmed: 23278653
ERJ Open Res. 2018 Mar 06;4(1):
pubmed: 29531957
J Allergy Clin Immunol. 2015 Apr;135(4):896-902
pubmed: 25441637
Ann Rheum Dis. 2016 Oct;75(10):1797-805
pubmed: 26857699
J Allergy Clin Immunol. 2018 May;141(5):1590-1597.e9
pubmed: 28797732
Am J Respir Crit Care Med. 2018 Jan 1;197(1):22-37
pubmed: 28910134
Thorax. 2010 Sep;65(9):787-94
pubmed: 20805172
N Engl J Med. 2009 Mar 5;360(10):973-84
pubmed: 19264686
J Allergy Clin Immunol. 2017 Jun;139(6):1797-1807
pubmed: 27773852
Lancet. 2018 Jan 27;391(10118):350-400
pubmed: 28911920
J Allergy Clin Immunol. 2014 Jun;133(6):1557-63.e5
pubmed: 24332216
Chest. 2020 Apr;157(4):790-804
pubmed: 31785254